Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice.
Magdalena Knetki-WróblewskaRafał DziadziuszkoTomasz JankowskiPaweł KrawczykMaciej BrylKatarzyna StencelAnna WronaArtur BanduraJolanta Smok-KalwatJolanta Rok-KnapińskaKinga Szydziak-ZwierzyńskaKrzysztof RogoziewiczGrzegorz CzyżewiczMonika WójtowiczMarek WojtukiewiczEwa KalinkaPiotr J WysockiMateusz ŁobaczJanusz MilanowskiHubert PawlikDariusz M KowalskiMaciej KrzakowskiPublished in: Frontiers in oncology (2024)
In the real world, patients can clinically benefit from immunochemotherapy, regardless of the expression of PD-L1 and the histological type. Other clinicopathological factors such as performance status, extent, and location of secondary lesions have prognostic significance.